Dr. Stefanie Aeppli
Medizinische Onkologie und Hämatologie · Dept. I
Phase 2/3 Randomized Study of Tebentafusp as Monotherapy and in Combination with Pembrolizumab Versus Investigator’s Choice in HLA-A*02:01-positive Participants with Previously Treated Advanced Melanoma (TEBE-AM)
Jan 26, 2024
Clinical Studies - Jan 26, 2024 - Dec 31, 2027
Ongoing
Project leader: Aeppli Stefanie
Members: Scherrer Julia, Quinter Janine
Muscle-invasive bladder cancer (MIBC) and perioperative treatment
May 13, 2022Diese Studie untersucht die Kombination der Standardtherapie für das muskelinvasive Blasenkarzinom (Chemotherapie gefolgt von einer Operation mit Entfernung der Harnblase) mit einer Immuntherapie mit Bacille Calmette Guérin (BCG) und Atezolizumab. BC...
Clinical Studies - May 13, 2022 - May 13, 2032
Ongoing
Project leader: Aeppli Stefanie
Members: Scherrer Julia, Müller Fiona
A PHASE II, MULTICENTRE, OPEN-LABEL STUDY OF CABOZANTINIB AS 2ND LINE TREATMENT IN SUBJECTS WITH UNRESECTABLE, LOCALLY ADVANCED OR METASTATIC RENAL CELL CARCINOMA WITH A CLEAR-CELL COMPONENT WHO PROGRESSED AFTER 1ST LINE TREATMENT WITH CHECKPOINT INHIBITORS
Jul 17, 2020Multizentrische Studie bei Patienten mit metastasiertem Nierenzellkarzinom nach Progredienz unter einer Erstli-nientherapie mit ICI/ICI oder ICI/TKI Kombination zur Eva-luation der Wirksamkeit und Verträglichkeit des Tyrosin-kinase Inhibitors Cabozan...
Clinical Studies - Jul 17, 2020 - Jul 17, 2022
Automatically Closed
Project leader: Rothermundt Christian
Members: Aeppli Stefanie, Fischer Stefanie, Omlin Aurelius
A Phase 3, Randomized, Double-blind Trial of Pembrolizumab (MK3475) Plus Enzalutamide Plus ADT Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic HormoneSensitive Prostate Cancer (mHSPC) (KEYNOTE-991)
Mar 3, 2020While many men diagnosed with locally confined disease may be treated definitively with radiation or surgery, ap-proximately 30% of men have recurrent disease and go on to develop metastatic prostate cancer. In addition, 5% to 30% of men with prostat...
Clinical Studies - Mar 3, 2020 - Mar 10, 2030
Ongoing
Project leader: Omlin Aurelius
Members: Rothermundt Christian, Aeppli Stefanie
A Phase 3, Randomized, Double-blind, Active-Comparator-Controlled Clinical Study of Adjuvant MK-7684A (Vibostolimab with Pembrolizumab) Versus Adjuvant Pembrolizumab in Participants with High-risk Stage II-IV Melanoma (KEYVIBE-010)
Mar 26, 23Diese Studie soll die Wirksamkeit und Sicherheit von ei-nem experimentellen Medikament MK-7684A (Vibosto-limab zusammen mit Pembrolizumab) im Vergleich zu MK-3475 (Pembrolizumab) allein, bei Patienten mit im Stadium IIB–IV (Hochrisiko-Melanom) unters...
Clinical Studies - Mar 26, 23 - Dec 21, 2030
Ongoing
Project leader: Aeppli Stefanie
Members: Sennhauser Andrina